Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Carmen Dulce Da Silveira Brás Silva Ribeiro

    Autor

Participantes de fora da FMUP

  • Willer, ASM
  • Santos-Gomes, J
  • Adao, R
  • Eyries, M
  • Pérez-Vizcaino, F
  • Capuano, V
  • Montani, D
  • Antigny, F

Unidades de investigação

Abstract

Potassium channel subfamily K member 3 (KCNK3), encoded by the KCNK3 gene, is part of the two-pore domain potassium channel family, constitutively active at resting membrane potentials in excitable cells, including smooth muscle and cardiac cells. Several physiological and pharmacological mediators, such as intracellular signalling pathways, extracellular pH, hypoxia and anaesthetics, regulate KCNK3 channel function. Recent studies show that modulation of KCNK3 channel expression and function strongly influences pulmonary vascular cell and cardiomyocyte function. The altered activity of KCNK3 in pathological situations such as atrial fibrillation, pulmonary arterial hypertension and right ventricular dysfunction demonstrates the crucial role of KCNK3 in cardiovascular homeostasis. Furthermore, loss of function variants of KCNK3 have been identified in patients suffering from pulmonary arterial hypertension and atrial fibrillation. This review focuses on current knowledge of the role of the KCNK3 channel in pulmonary circulation and the heart, in healthy and pathological conditions.

Dados da publicação

ISSN/ISSNe:
0022-3751, 1469-7793

JOURNAL OF PHYSIOLOGY-LONDON  Wiley-Blackwell Publishing Ltd

Tipo:
Review
Páginas:
3717-3737
Link para outro recurso:
www.scopus.com

Citações Recebidas na Scopus: 7

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • atrial fibrillation; K2P3.1; mutation; pulmonary hypertension; TASK-1; ventricular function

Financiamento

Proyectos asociados

Persistent Pulmonary Hypertension of the Newborn: Pathophysiological mechanisms and novel therapeutic approaches

Investigador Principal: Carmen Dulce da Silveira Brás Silva Ribeiro

Estudo Clínico Académico . 2020

An overview of circulating pulmonary arterial hypertension biomarkers

Investigador Principal: Carmen Dulce da Silveira Brás Silva Ribeiro

Estudo Clínico Académico . 2022

Heart Failure with preserved ejection fraction: a pharmacotherapeutic update

Investigador Principal: Carmen Dulce da Silveira Brás Silva Ribeiro

Estudo Clínico Académico . 2022

Pthological rola of urocortin-2 in pulmonaryn hypertension - therapeutic implications

Investigador Principal: Carmen Dulce da Silveira Brás Silva Ribeiro

Estudo Clínico Académico . 2020

Citar a publicação

Partilhar a publicação